Challenges Facing JAK Inhibitor Therapy for Myeloproliferative Neoplasms

被引:50
作者
Tefferi, Ayalew [1 ]
机构
[1] Mayo Clin, Div Hematol, Dept Med, Rochester, MN 55905 USA
关键词
MYELOFIBROSIS; MUTATION; TET2;
D O I
10.1056/NEJMe1115119
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
引用
收藏
页码:844 / 846
页数:3
相关论文
共 10 条
[1]
Mutation in TET2 in Myeloid Cancers [J].
Delhommeau, Francois ;
Dupont, Sabrina ;
Della Valle, Veronique ;
James, Chloe ;
Trannoy, Severine ;
Masse, Aline ;
Kosmider, Olivier ;
Le Couedic, Jean-Pierre ;
Robert, Fabienne ;
Alberdi, Antonio ;
Lecluse, Yann ;
Plo, Isabelle ;
Dreyfus, Francois J. ;
Marzac, Christophe ;
Casadevall, Nicole ;
Lacombe, Catherine ;
Romana, Serge P. ;
Dessen, Philippe ;
Soulier, Jean ;
Viguie, Franck ;
Fontenay, Michaela ;
Vainchenker, William ;
Bernard, Olivier A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (22) :2289-2301
[2]
JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis [J].
Harrison, Claire ;
Kiladjian, Jean-Jacques ;
Al-Ali, Haifa Kathrin ;
Gisslinger, Heinz ;
Waltzman, Roger ;
Stalbovskaya, Viktoriya ;
McQuitty, Mari ;
Hunter, Deborah S. ;
Levy, Richard ;
Knoops, Laurent ;
Cervantes, Francisco ;
Vannucchi, Alessandro M. ;
Barbui, Tiziano ;
Barosi, Giovanni .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (09) :787-798
[3]
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera [J].
James, C ;
Ugo, V ;
Le Couédic, JP ;
Staerk, J ;
Delhommeau, F ;
Lacout, C ;
Garçon, L ;
Raslova, H ;
Berger, R ;
Bennaceur-Griscelli, A ;
Villeval, JL ;
Constantinescu, SN ;
Casadevall, N ;
Vainchenker, W .
NATURE, 2005, 434 (7037) :1144-1148
[4]
Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis [J].
Pardanani, Animesh ;
Gotlib, Jason R. ;
Jamieson, Catriona ;
Cortes, Jorge E. ;
Talpaz, Moshe ;
Stone, Richard M. ;
Silverman, Michael H. ;
Gilliland, D. Gary ;
Shorr, Jolene ;
Tefferi, Ayalew .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07) :789-796
[5]
Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1 [J].
Tefferi, A. .
LEUKEMIA, 2010, 24 (06) :1128-1138
[6]
One Thousand Patients With Primary Myelofibrosis: The Mayo Clinic Experience [J].
Tefferi, Ayalew ;
Lasho, Terra L. ;
Jimma, Thitina ;
Finke, Christy M. ;
Gangat, Naseema ;
Vaidya, Rakhee ;
Begna, Kebede H. ;
Al-Kali, Aref ;
Ketterling, Rhett P. ;
Hanson, Curtis A. ;
Pardanani, Animesh .
MAYO CLINIC PROCEEDINGS, 2012, 87 (01) :25-33
[7]
Long-Term Outcome of Treatment with Ruxolitinib in Myelofibrosis [J].
Tefferi, Ayalew ;
Litzow, Mark R. ;
Pardanani, Animesh .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (15) :1455-1457
[8]
Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study [J].
Tefferi, Ayalew ;
Vaidya, Rakhee ;
Caramazza, Domenica ;
Finke, Christy ;
Lasho, Terra ;
Pardanani, Animesh .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (10) :1356-1363
[9]
A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis [J].
Verstovsek, Srdan ;
Mesa, Ruben A. ;
Gotlib, Jason ;
Levy, Richard S. ;
Gupta, Vikas ;
DiPersio, John F. ;
Catalano, John V. ;
Deininger, Michael ;
Miller, Carole ;
Silver, Richard T. ;
Talpaz, Moshe ;
Winton, Elliott F. ;
Harvey, Jimmie H., Jr. ;
Arcasoy, Murat O. ;
Hexner, Elizabeth ;
Lyons, Roger M. ;
Paquette, Ronald ;
Raza, Azra ;
Vaddi, Kris ;
Erickson-Viitanen, Susan ;
Koumenis, Iphigenia L. ;
Sun, William ;
Sandor, Victor ;
Kantarjian, Hagop M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (09) :799-807
[10]
Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis. [J].
Verstovsek, Srdan ;
Kantarjian, Hagop ;
Mesa, Ruben A. ;
Pardanani, Animesh D. ;
Cortes-Franco, Jorge ;
Thomas, Deborah A. ;
Estrov, Zeev ;
Fridman, Jordan S. ;
Bradley, Edward C. ;
Erickson-Viitanen, Susan ;
Vaddi, Kris ;
Levy, Richard ;
Tefferi, Ayalew .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (12) :1117-1127